Effects of somatostatin analog on splanchnic hemodynamics and plasma glucagon level in portal hypertensive rats

doi:10.3748/wjg.v3.i4.218

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2205)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

225

HTML

1812

Tables (1-3)

168

Sum=2205

Dec 15, 1997 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Research

World J Gastroenterol. Dec 15, 1997; 3(4): 218-220
Published online Dec 15, 1997. doi: 10.3748/wjg.v3.i4.218

Table 1 Effects of octreotide on splanchnic hemodynamics

	Normal Cont	IHPH Cont	IHPH Thera	PHPH Cont	PHPH Thera
THBF, mL/min/100 g BW	6.30 ± 0.5	5.86 ± 0.9	4.53 ± 0.9^c	2.80 ± 0.3^a	2.12 ± 0.4^e
THBF, mL/min/g LW	2.50 ± 0.3	1.61 ± 0.3^a	1.37 ± 0.3^a	1.17 ± 0.2^ae	0.09 ± 0.2^ae
PVI, mL/min/100 g BW	4.85 ± 0.4	7.03 ± 0.7^a	5.85 ± 0.6^c	7.86 ± 0.4^ae	5.38 ± 0.6^ca
SVR, mmHg·min/mL·100 g BW	26.68 ± 2.1	15.86 ± 2.3^a	20.64 ± 2.8^c	12.84 ± 1.0^a	19.88 ± 2.4^ca
PVR, mmHg·min/mL·100 g BW	1.72 ± 0.2	2.01 ± 0.3^a	1.95 ± 0.2^a	1.76 ± 0.1^e	2.20 ± 0.3^c
PSS, %	1.46 ± 0.3	34.29 ± 11.7^a	38.77 ± 11.2^a	94.4 ± 1.3^ae	87.7 ± 4.5

^aP < 0.05 vs unmodeled/untreated normal controls; ^cP < 0.05 vs control group; ^eP < 0.05 vs the IHPH control group. Cont: Control; Thera: Therapy; THBF: Total hepatic blood flow; PVI: Portal venous inflow; SVR: Splanchnic vascular resistance; PVR: Portal venous resistance; PSS: Portosystemic shunt.

Table 2 Effects of octreotide on splanchnic blood flow (mL·g·min)

	Normal Cont	IHPH Cont	IHPH Thera	PHPH Cont	PHPH Thera
Stomach	0.59 ± 0.1	0.76 ± 0.2^a	0.59 ± 0.1^c	0.71 ± 0.1^a	0.53 ± 0.1^c
Intestine and mesentery	1.36 ± 0.1	1.65 ± 0.1^a	1.11 ± 0.1^a^c	1.83 ± 0.2^a	1.21 ± 0.1^a^c
Pancreas	0.84 ± 0.1	0.97 ± 0.1^a	0.62 ± 0.1^c	1.27 ± 0.2^a	1.01 ± 0.2^c
Spleen	0.98 ± 0.4	0.78 ± 0.2	0.46 ± 0.2^a^c	0.96 ± 0.2	0.72 ± 0.2^c
Liver	0.58 ± 0.1	0.38 ± 0.1^a	0.28 ± 0.1^a^c	0.99 ± 0.1^a^e	0.62 ± 0.1^c

^aP < 0.05 vs unmodeled/untreated normal controls;

^cP < 0.05 vs control group;

^eP < 0.05 vs the IHPH control group.

Table 3 Effects of octreotide on plasma glucagon levels (ng/L)

	Peripheral Vein	Portal Vein
Normal Cont	19.28 ± 2.5	44.25 ± 6.1
IHPH Cont	49.37 ± 10.6^a	180.25 ± 31.2^a
IHPH Thera	40.12 ± 14.6^a	140.96 ± 41.9^a
PHPH Cont	69.82 ± 17.2^a	143.60 ± 25.6^a
PHPH Thera	50.08 ± 7.6^a	106.33 ± 37.9^a

^aP < 0.05 vs unmodeled/untreated normal controls.

Citation: Wu ZY, Zhao XJ, Jiao Z, Chen ZP, Kuang YL. Effects of somatostatin analog on splanchnic hemodynamics and plasma glucagon level in portal hypertensive rats. World J Gastroenterol 1997; 3(4): 218-220
URL: https://www.wjgnet.com/1007-9327/full/v3/i4/218.htm
DOI: https://dx.doi.org/10.3748/wjg.v3.i4.218